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The etiology of biliary atresia (BA) is unknown. Given that patterns of anomalies might
provide etiopathogenetic clues, we used data from the North American Childhood Liver
Disease Research and Education Network to analyze patterns of anomalies in infants with
BA. In all, 289 infants who were enrolled in the prospective database prior to surgery at
any of 15 participating centers were evaluated. Group 1 was nonsyndromic, isolated BA
(without major malformations) (n 5 242, 84%), Group 2 was BA and at least one mal-
formation considered major as defined by the National Birth Defects Prevention Study
but without laterality defects (n 5 17, 6%). Group 3 was syndromic, with laterality
defects (n 5 30, 10%). In the population as a whole, anomalies (either major or minor)
were most prevalent in the cardiovascular (16%) and gastrointestinal (14%) systems.
Group 3 patients accounted for the majority of subjects with cardiac, gastrointestinal, and
splenic anomalies. Group 2 subjects also frequently displayed cardiovascular (71%) and
gastrointestinal (24%) anomalies; interestingly, this group had genitourinary anomalies
more frequently (47%) compared to Group 3 subjects (10%). Conclusion: This study
identified a group of BA (Group 2) that differed from the classical syndromic and non-
syndromic groups and that was defined by multiple malformations without laterality
defects. Careful phenotyping of the patterns of anomalies may be critical to the interpre-
tation of both genetic and environmental risk factors associated with BA, allowing new
insight into pathogenesis and/or outcome. (HEPATOLOGY 2013;58:1724-1731)
T
he etiology of biliary atresia (BA) is unknown.
In a large series of European infants reported by
Davenport et al.,1 infants with BA were
catalogued by two different presentations: acquired/
perinatal/nonsyndromic (90%) versus embryonal/syn-
dromic (10%). Infants with splenic malformation
(SM) and associated laterality defects were placed in the
latter category, implying that the pathogenetic and de-
velopmental features of the two types of BA probably
differed. In contrast, investigators from Taiwan
described the BASM syndrome in only 0.7% of BA
infants, whereas a total of 15.4% had other major
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congenital anomalies, suggesting different etiopatholo-
gies.2 The number of potential etiologies that explain the
pathogenesis of BA has expanded as the sophistication of
scientific methods to detect them has evolved. The viral
etiology hypothesis has been supported by a number of
reports, such as the finding of cytomegalovirus in the liv-
ers of BA infants3 and characterization of the rotavirus-
induced murine model of BA.4,5 Other investigators
have suggested an important role for primary immuno-
logic dysfunction, possibly secondary to maternal micro-
chimerism.6 One hypothesis unifying the viral and
immune dysfunction concept is that an in utero or peri-
natal viral infection may trigger an autoimmune attack
on the biliary epithelium.7 Still other groups have used
new technologies to examine genetic susceptibility to
BA. Leyva-Vega et al.8 reported overlapping heterozygous
deletions of chromosome 2q37.3 in two BA patients; the
etiologic significance of these abnormalities is unclear. A
genome-wide association study demonstrated a BA sus-
ceptibility locus on chromosome10q24.9 Recent animal
and human evidence support a role for epigenetic regula-
tion of interferon-gamma signaling in BA.10 Kohsaka
et al.11 found human JAG1 missense mutations in about
10% of their BA patients and noted an association of
these mutations with a severe phenotype. Hartley et al.12
suggested that the most likely etiopathogenetic explana-
tion of BA is that there are multiple mechanisms of bili-
ary injury leading ultimately to the one common
phenotype of obliterative cholangiopathy.
Given that there well may be more than two forms
of BA, we believe that a critical reappraisal of the
anomalies associated with BA could provide useful clues
as to the etiopathogenesis of the disease and have fol-
lowed the guidelines which the Center for Disease Con-
trol used in the National Birth Defects Prevention
Network. This network was established in 1997 in
order provide uniform reporting of birth defects that
might then be linked to a common etiology. Major
birth defects were defined by the following criteria: “a)
considered to be a major defect (affecting survival,
requiring substantial medical care, or resulting in
marked physiological or psychological impairment); b)
usually identifiable in the first 6 weeks of life (may be
extended for some defects); and c) consistently classi-
fiable.”13 In an attempt to identify environmental causes
of a given disease process (such as toxins or viral infec-
tions) as well as genetic causes, the Center for Disease
Control has followed the principle that careful homoge-
nous case definition is the optimum way to identify risk
factors and that etiologies of disease conditions such as
biliary atresia are likely to be distinct for isolated cases
without other major birth defects (our Group 1: no
major anomalies), cases associated with other major
birth defects but not syndromes (our Group 2: major
anomalies without laterality defects) versus cases associ-
ated with stereotypical anomalies (our Group 3: major
anomalies with laterality defects.14
The purpose of this study was to use data from the
large prospective multicenter study of BA of the North
American Childhood Liver Disease Research Network
(ChiLDREN) to perform a detailed analysis of con-
genital anomalies associated with BA. A sub-aim was
to determine if certain demographic variables were
associated with the subgroups of BA.
Patients and Methods
Subjects. Infants with suspected BA were enrolled
into a prospective longitudinal study of cholestasis in
infancy (PROBE: Clinicaltrials.gov NCT00061828)
prior to diagnostic surgery at any of 15 centers partici-
pating in ChiLDREN. The diagnosis of BA was con-
firmed by intraoperative cholangiogram and surgical
exploration prior to Kasai hepatoportenterostomy. In
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addition, the central Pathology Committee of the net-
work supported the diagnosis of BA by blinded review
of liver biopsies, coupled with examination of the bili-
ary remnants in cases where the biopsy was uncertain.
Determination of each associated anomaly was made
from information gathered at the time of surgery, by
review of imaging and other clinical studies, and by
physical examination. When a discrepancy was identi-
fied (e.g., no mention of polysplenia made on ultra-
sound versus polysplenia noted at the time of surgery),
a three-person adjudication committee determined the
credibility of evidence. After review of all the data col-
lected on a patient, infants were assigned to one of
three groups. Group 1 was isolated BA (without major
malformations and with a single spleen), Group 2 was
BA without laterality defects but with other congenital
malformations, including at least one malformation
considered major as defined by the National Birth
Defects Prevention Study.13 Group 3 was BA with one
or more laterality defects. These defects included splenic
abnormalities (asplenia, polysplenia, right-sided spleen,
or a double spleen), cardiovascular anomalies (dextrocar-
dia, mesocardia, total or partial anomalous pulmonary
venous return [TAPVR/PAPVR], absent or interrupted
inferior vena cava [IVC], anomalous/bilateral superior
vena cava [SVC]), and/or preduodenal portal vein and
gastrointestinal anomalies (“abdominal heterotaxy,” mid-
line/transverse liver, right-sided stomach, intestinal mal-
rotation, and anomalous or annular pancreas).15
All children in this study were enrolled between
May 29, 2004 and November 1, 2010. Written
informed consent was obtained from the parent/legal
guardian of each patient and the study protocol con-
formed to the ethical guidelines of the 1975 Declara-
tion of Helsinki as reflected by approval by the
Institutional Review Committees at each site.
Demographic and Clinical Variables. Extensive
demographic information was collected prospectively for
each subject. This information included maternal age,
paternal age, parity, and fetal exposure to drugs (includ-
ing prescribed, over-the-counter, recreational, and herbal
preparations) and gestational diabetes. Location of the
home during the pregnancy was categorized as rural,
urban, or suburban. Family history included the pres-
ence of autoimmune diseases among the primary family
and first-degree relatives and the frequency of autoim-
munity in family members was calculated (percent of
patients with at least one first-degree relative with auto-
immune disease). Both mothers and fathers were asked
if any first-degree relatives had one or more of the auto-
immune diseases listed in Table 1. Information collected
about the child included birth weight, birth length, and
sequential laboratory tests from the time of presentation
to the evaluation by the specialist. All laboratory tests are
reported as measured except that globulin was inferred
by subtraction of albumin from total protein.
Analytic Methods. Descriptive data were summar-
ized by means and SDs for continuous variables and
as percentages for categorical variables. The data were
summarized overall, as well as within each of the three
BA groups. In addition to the descriptive analyses, several
factors were evaluated for differences across the BA
groups. For the continuous variables, analysis of variance
was used to assess overall differences among the groups.
Where the F-test reached statistical significance (P <
0.1), pairwise comparisons were made for the three BA
groups to ascertain specific differences. The categorical
variables were assessed by chi-square tests where evidence
of general association (P < 0.1) was further explored
through pairwise comparisons of the three groups. All
analyses were performed using SAS (SAS Institute, 2008,
SAS/STAT 9.2 User’s Guide, Cary, NC).
Results
Three Distinct BA Groups Identified. The major-
ity of patients with BA were within Group 1, isolated
BA without associated major malformations (242/289,
84%). Group 2, BA without laterality defects but with
at least one major malformation, encompassed 17 of the
289 BA patients (6%), and Group 3, BA with one or
more laterality defects, encompassed 30 of 289 patients
(10%). Table 2 summarizes the most common major
and minor anomalies reported by system in all 289 sub-
jects and in each of the three groups. Overall, anomalies
were most prevalent in the cardiovascular (16% of
Table 1. Autoimmune Diseases in First-Degree Relatives
About Which Parents Were Queried
Autoimmune liver disease
Primary biliary cirrhosis
Primary sclerosing cholangitis
Autoimmune hepatitis
Autoimmune and connective tissue disease
Systemic lupus erythematosus
Raynaud’s syndrome
Rheumatoid arthritis
Multiple sclerosis
Sjogren’s syndrome
Polymyositis
Autoimmune endocrine diseases
Insulin-dependent diabetes in subjects <30 years old
Thyroid disease including hypothyroid, goiter, thyrotoxicosis, and
thyroid disease type unknown
Autoimmune gastrointestinal diseases
Ulcerative colitis
Crohn’s disease
Other unspecified autoimmune disease
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subjects), and gastrointestinal (14%) systems and splenic
anomalies (7%). Group 3 patients with laterality defects
accounted for the majority of subjects with cardiac, gas-
trointestinal, and splenic anomalies. Splenic anomalies
were noted in 70% of Group 3 patients.
Group 2 subjects, while also displaying significant
cardiovascular (71%) and gastrointestinal (24%) anoma-
lies, also had significant genitourinary (47%) anomalies
that were uncommon in Group 3 subjects. The most
common genitourinary defects found in this group were
cystic kidney and hydronephrosis. Four of the Group 2
patients had vertebral and rib anomalies but only one
had a major musculoskeletal anomaly (longitudinal
limb deficiency). The cardiovascular anomalies in
Group 2 included aortic arch abnormalities, aortic co-
arctation, atrial septal defects, patent ductus arteriosus,
patent foramen ovale, pulmonary artery stenosis, pul-
monary valvular stenosis, Tetralogy of Fallot, transposi-
tion of the great vessels, and ventricular septal defect.
Gastrointestinal anomalies included duodenal/jejuna
atresia, esophageal atresia, and imperforate anus. Sup-
porting Table S1 summarizes the distribution of the sys-
tems with at least one reported anomaly for the 47
individual patients in Groups 2 and 3. Supporting Ta-
ble S2 summarizes the distribution of specific genitouri-
nary anomalies across all three groups.
Demographic Variables Associated With BA
Groups. Analysis of demographic variables between
groups revealed significant differences in the age at first
evaluation, with Group 1 having a later age at evalua-
tion compared to Group 3 (Table 3). Recreational drug
use during pregnancy was reported more commonly in
Group 3 compared to Group 1. There was no differ-
ence between the three groups for mother’s or father’s
age, gender, race, history of familial autoimmune dis-
ease, z-scores for birth weight or length, or rural versus
urban location. For gestational age, the difference across
the three groups was significant (F test P 5 0.0912).
Subsequent pairwise comparison revealed Group 1
infants tended to be slightly older than Group 3 infants
(P 5 0.0512). The mean maternal age was 29.2 6 6.0
years and the mean paternal age was 31.9 6 7.0 years.
The incidence of gestational diabetes was increased in
Group 3 compared to Group 1. Interestingly, the inci-
dence of an autoimmune disease in first-degree relatives
was substantial: 44% overall, with no difference
between groups. Sixty-three percent of the whole popu-
lation of BA infants was white, without differences
between the three groups. The race/ethnicity distribu-
tion was relatively even across groups but the small
sample size makes it difficult to compare anything other
than white versus nonwhite.
Clinical Laboratory Variables Associated With BA
Groups. Table 4 reports select clinical and laboratory
variables that were prospectively collected. While total
bilirubin did not differ across the three groups, there
was a difference in direct bilirubin across groups (F
test P 5 0.0693). Group 1 infants tended to have a
higher direct bilirubin values compared to Group 2
and Group 3, although neither of these pairwise com-
parison reached significance at the P 5 0.05 threshold
(P 5 0.0999 and P 5 0.0654, respectively). Gamma-
glutamyl transpeptidase (GGTP) was similar across the
groups. Alkaline phosphatase was significantly higher
in Group 1 compared to Group 2. After adjusting for
age at first evaluation, these laboratory differences
across the groups remained (data not shown).
Total protein and albumin levels were higher in
Group 1 compared to Group 3. Alanine aminotrans-
ferase was lower in Group 2. Group 3 was character-
ized by higher white blood cell counts and platelet
counts versus the other two groups.
Discussion
In this prospective North American multicenter
study of BA, we identified three groups of BA patients.
The most common was isolated BA, the perinatal or
acquired form of BA without associated major malfor-
mations (Group 1). A second group was identified
whereby not only gastrointestinal and cardiac anoma-
lies were associated with BA in the absence of laterality
Table 2. Frequency of Congenital Anomalies in 289 Biliary Atresia Patients by Group
Any Anomaly
Total
Group 1 (Without Major
Anomalies)
Group 2 (Major
Anomalies Without
Laterality Defects)
Group 3 (Laterality
Defects)
N % N % N % N %
289 242 17 30
Cardiovascular 47 16.3 11 4.5 12 70.6 24 80.0
Pulmonary 4 1.4 1 0.4 1 5.9 2 6.7
Gastrointestinal 40 13.8 9 3.7 4 23.5 27 90.0
Genitourinary 15 5.2 4 1.7 8 47.1 3 10.0
Splenic anomaly 21 7.3 0 0 0 0 21 70.0
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defects, but also findings of genitourinary anomalies
(Group 2). The most frequent renal anomalies
reported in Group 2 were cystic kidneys or hydro-
nephrosis. The observation that as many as 16% of
children with BA may have heart disease and 3% may
have renal anomalies makes differentiation from Ala-
gille syndrome difficult. Likewise, the fact that infants
with BA may occasionally have cystic kidneys may
make differentiation from infants with polycystic liver-
kidney disease a bit of a challenge, although cholestasis
is rare in the latter condition. The incidence of clini-
cally significant hydronephrosis in otherwise healthy
newborns is 1 in 600 live births (0.17%).16,17 The
incidence of hydronephrosis in BA patients in this
study (all within Group 2) was 3 in 289 (1%), an
almost 10-fold greater incidence compared to the gen-
eral population. There is scant recent literature on gen-
itourinary and musculoskeletal abnormalities associated
with BA. A case report described an infant with
BASM, sacro-coccygeal agenesis, clubfoot, and ano-uri-
nary incontinence.18 A BA patient with anorectal agen-
esis and a complicated urogenital malformation was
also described.9 It is known that many genitourinary
anomalies are associated with concurrent vertebral seg-
mentation anomalies.20
In our study of Group 2 patients with genitourinary
and musculoskeletal abnormalities, a similar association
to that previously reported in the literature is sug-
gested. In addition, some in Group 1 had clinically in-
significant rib or vertebral defects. Twenty years ago
Carmi et al.21 reported that one-third of their 51 BA
patients with major anomalies had laterality defects
but two-thirds had cardiac, genitourinary, and muscu-
loskeletal defects not associated with laterality defects.
Our report confirms their findings, extends the spec-
trum of renal anomalies observed, and also strongly
reinforces the authors’ suggestion that there is etiologic
heterogeneity in BA.
Table 3. Clinical and Demographic Characteristics of 289 Infants With Biliary Atresia
Parameter N Mean 6 SD or N (%)
P Value vs.
Group 2
P Value vs.
Group 3
Gender (male vs. female) (P 5 0.4063) 289 135 (46.7%) — —
BA Group 1 242 109 (45.0%) — —
BA Group 2 17 10 (58.8%) — —
BA Group 3 30 16 (53.3%) — —
Birth weight kg (P 5 0.4079) 269 3.15 6 0.57 — —
BA Group 1 223 3.16 6 0.54 — —
BA Group 2 16 3.25 6 0.56 — —
BA Group 3 30 3.03 6 0.78 — —
Birth length cm (P 5 0.2858) 252 49.8 6 3.6 — —
BA Group 1 211 49.9 6 3.6 — —
BA Group 2 15 49.2 6 2.6 — —
BA Group 3 26 48.8 6 4.0 — —
Gestational age in weeks (P 5 0.0912)* 271 38.2 6 2.2 — —
BA Group 1 226 38.3 6 2.2 0.2448 0.0512
BA Group 2 17 37.6 6 2.1 — 0.7471
BA Group 3 28 37.4 6 2.3 0.7471 —
Age at first evaluation (days) (P 5 0.0397*) 288 68.1 6 36.3 — —
BA Group 1 242 70.4 6 37.6 0.2181 0.0204
BA Group 2 16 58.9 6 27.8 — 0.6688
BA Group 3 30 54.2 6 24.7 0.6688 —
Recreational drug use during pregnancy (P 5 0.0964*) 276 10 (3.6%) — —
BA Group 1 230 6 (2.6%) 0.4325 0.0321
BA Group 2 17 1 (5.9%) — 0.6041
BA Group 3 29 3 (10.3%) 0.6041 —
Rural vs. urban (P 5 0.4650) 280 230 (82.1%) — —
BA Group 1 234 191 (81.6%) — —
BA Group 2 26 22 (84.6%) — —
BA Group 3 20 17 (85.0%) — —
Gestational diabetes (yes vs. no) (P < 0.0948*) 279 32 (11.5%) — —
BA Group 1 232 23 (9.9%) 0.8064 0.0298
BA Group 2 17 2 (11.8%) — 0.3328
BA Group 3 30 7 (23.3%) 0.3328 —
*Significant at a 5 0.1 for differences across BA groups.. Pairwise comparisons were assessed.
BA Group 1, n 5 242: infants without major anomalies.
BA Group 2, n 5 17: infants with major anomalies without laterality defects.
BA Group 3, n 5 30: infants with laterality defects.
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In a large study from England the incidence of sple-
nic anomalies was 10.2%,1 almost identical to the inci-
dence identified in this study. The investigators from
England also reported similar rates of intestinal malro-
tation, absent or interrupted IVC, and preduodenal
portal vein in patients with splenic anomalies. Fifteen
percent of the patients in their series with laterality
defects were born to mothers with diabetes and this
association was not found in their BA patients without
laterality defects. Gestational diabetes was observed in
9.9%, 11.8%, and 23.3% of our infants in Groups 1,
2, and 3. Interestingly, the English study also found a
female predominance of 2:1 in patients with splenic
anomalies, a finding that was not identified in our
North American cohort. As noted in the article by
Davenport et al.,1 in addition to “BASM,” another
term for infants with BA and stereotypical syndromic
abdominal and vascular anomalies is “biliary atresia
laterality sequence.” Given that only 70% of our
patients with laterality defects actually had splenic
anomalies, the latter term might be preferable in the
future to “BASM” to describe this stereotypical group
of infants.
The Canadian Pediatric Hepatology Research group
has recently reported their analysis of 382 infants with
BA and the associated anomalies.22 Forty-four (13%)
had associated anomalies, only 25 (6.5%) of which
were associated with SM. The authors concluded that
BA infants with anomalies demonstrated a spectrum of
laterality defects and suggested that the meaning of the
acronym BASM be modified to “biliary atresia struc-
tural malformation.” Our conclusions are somewhat
Table 4. Selected Laboratory Characteristics of 289 Infants With Biliary Atresia
Parameter N Mean 6 SD P Value vs. Group 2 P Value vs. Group 3
Total bilirubin (P 5 0.4777) 277 8.43 6 3.48
BA Group 1 231 8.53 6 3.54
BA Group 2 17 8.29 6 3.44
BA Group 3 29 7.70 6 3.01
Direct bilirubin (P 5 0.0693)* 167 5.68 6 2.29
BA Group 1 138 5.87 6 2.22 0.0999 0.0758
BA Group 2 12 4.74 6 2.49 0.9184
BA Group 3 17 4.83 6 2.51 0.9184
GGTP (P 5 0.3921) 262 686.8 6 533.4
BA Group 1 217 692.2 6 530.6
BA Group 2 16 802.0 6 669.5
BA Group 3 29 582.4 6 470.2
Alkaline phosphatase (P 5 0.0010)* 272 589.6 6 315.5
BA Group 1 226 608.3 6 316.6 0.0007 0.0654
BA Group 2 17 342.5 6 131.6 0.1056
BA Group 3 29 495.6 6 316.0 0.1056
Total protein (P 5 0.0140)* 213 6.00 6 0.82 — —
BA Group 1 176 6.07 6 0.81 0.1121 0.0094
BA Group 2 15 5.73 6 0.96 — 0.6263
BA Group 3 22 5.60 6 0.59 0.6263 —
Albumin (P 5 0.0003)* 268 3.56 6 0.54 — —
BA Group 1 224 3.62 6 0.51 0.0026 0.0034
BA Group 2 17 3.22 6 0.66 — 0.5895
BA Group 3 27 3.30 6 0.57 0.5895 —
ALT (P 5 0.0299)* 276 150 6 112 — —
BA Group 1 230 153 6 101 0.0117 0.5534
BA Group 2 17 83 6 50 — 0.0141
BA Group 3 29 166 6 189 0.1041 —
WBC (P 5 0.0121)* 267 13.67 6 4.54 — —
BA Group 1 223 13.41 6 4.33 0.7998 0.0034
BA Group 2 16 13.11 6 3.91 — 0.0369
BA Group 3 28 16.06 6 5.76 0.0369 —
Platelets (P 5 0.0416)* 266 432.0 6 178.1 — —
BA Group 1 224 426.1 6 165.2 0.3511 0.0238
BA Group 2 15 382.1 6 172.9 — 0.0278
BA Group 3 27 508.0 6 256.0 0.0278 —
*Significant at a 5 0.1. Pairwise comparisons were assessed.
BA Group 1, n 5 242: infants without major anomalies.
BA Group 2, n 5 17: infants with major anomalies without laterality defects.
BA Group 3, n 5 30: infants with laterality defects.
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similar in that a total of 16% of our infants were in
the anomaly Groups 2 and 3. On the other hand, the
main difference between our observations and those of
the Canadian group was that Group 2 infants fre-
quently exhibited major birth defects of the genitouri-
nary and/or gastrointestinal systems, not considered
part of defective lateralization, suggesting that this
group may represent a different etiopathogenesis than
Groups 1 and 3.
Group 3 infants were younger at the time of initial
evaluation compared to Group 1. The associated
anomalies in Group 3, especially the cardiac lesions
associated with murmurs or cyanosis, probably brought
the patient to medical attention sooner than the
infants with isolated cholestasis.
An unexpected finding was the high incidence of
autoimmunity in first-degree relatives of all BA groups
(average 44%). The occurrence of autoimmune dis-
eases in relatives provides circumstantial evidence that
a candidate disease (i.e., BA) may be autoimmune in
nature.23 The incidence of autoimmunity in first-
degree relatives is much higher than that found in the
general population, where autoimmunity rates vary
from 2.5%-9%.26,27 Importantly, the incidence of
autoimmunity in first-degree relatives of BA patients
was similar to the rate of 37%-43% identified in auto-
immune hepatitis26 and 25.5% in type-1 diabetes mel-
litus.25 This intriguing finding of autoimmunity in
first-degree relatives of BA patients warrants further
investigation. The fact that there was no difference in
autoimmunity rates between the three groups suggests
that the autoimmune hypothesis of BA may be rele-
vant to the pathogenesis of all types of BA and is a
clue to be pursued in further studies. It is also possibly
that the high incidence simply resulted from our rigor-
ous questionnaire containing a long list of autoim-
mune diseases and not being of pathogenetic
significance. We agree that the lack of differences
between groups is not only at variance to explain the
autoimmune hypothesis of Group 1 but also at var-
iance to explain the genetic, nonimmune hypothesis of
syndromic BA, in which lower familial rates of auto-
immune disease would have been expected. Possible
explanations include the possibility that this hypothesis
is incorrect versus the immune dysregulation hypothe-
sized for Group 1 BA27 being atypical from the usual
types of familial autoimmune diseases.
The analysis of laboratory tests revealed no differ-
ence in total bilirubin across the groups, although
infants in Group 1 had higher alkaline phosphatase lev-
els and they also tended to have higher direct bilirubin
values. The significance of this observation is
uncertain. Group 1 infants tended to be older at the
time of initial evaluation and thus could be hypothe-
sized to have a longer duration of obstruction. We
explored this possibility by adjusting for age at first
evaluation and the laboratory differences across the
groups remained, suggesting age alone was not re-
sponsible. Group 1 infants had higher total serum al-
bumin levels compared to Groups 2 and 3. It has
been reported that newborns have lower albumin lev-
els that increase with age.28 Both Groups 2 and 3
were younger at the time of evaluation compared to
Group 1 and the younger age at presentation may
explain the lower albumin levels. Furthermore, it is
possible that increased protein and albumin losses
could be associated with some of the anomalies pres-
ent in Groups 2 and 3. Specifically, intestinal atresias
could lead to intestinal protein loss and renal anoma-
lies could result in urinary protein loss. Finally,
higher total white cell counts and platelet counts
were identified in Group 3 compared to the others.
The hemodynamics within the spleen in polysplenia
are most likely altered and it is theorized that
decreased filtration through the splenic venules would
be associated with decreased trapping and removal of
white cells and platelets.
In summary, BA is a heterogeneous disease that is
composed of at least three subgroups. This study identi-
fied a group that was defined by multiple malformations
including genitourinary anomalies, reinforcing a similar
report by Carmi et al. in 1993.21 Future investigations
are indicated to determine if each of these subtypes is
associated with unique predisposition or etiology.
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